Navigation Links
Factor Bioscience Granted First U.S. Patent for RNA-Based Reprogramming Technology
Date:7/31/2013

CAMBRIDGE, Mass., July 31, 2013 /PRNewswire/ -- The United States Patent and Trademark Office today granted Factor Bioscience the first patent covering methods for reprogramming cells using RNA, a technology with wide-ranging applications in biological research and personalized medicine. The patented methods can transform patient skin cells into stem cells more rapidly, efficiently, and safely than previous techniques.

"Reprogramming is an amazing process, when it works," explains co-inventor Dr. Christopher Rohde, Chief Operating Officer and Director of High-Throughput Technologies. "However, previous methods were burdened by cumbersome protocols, poor reliability, and woeful inefficiency. Our RNA-reprogramming technology overcomes all of these limitations while being faster and safer than the best available techniques."

Excitement has been growing in the reprogramming field since Dr. Shinya Yamanaka's Nobel Prize-winning discovery in 2006 that infecting skin cells with a specific combination of viruses could reprogram them to a pluripotent stem-cell state. However, efforts to achieve the same goal without using the potentially mutation-causing viruses had, until this point, yielded mixed results. "Many researchers have attempted to develop a reliable DNA-free reprogramming method, and more than one have claimed success," says co-inventor Dr. Matt Angel, CEO. "In every case, the reported method turned out to be unreliable at best, and more often than not, completely irreproducible. The grant of the first patent covering reliable DNA-free reprogramming technology brings us one step closer to the development of therapeutics based on safely reprogrammed cells."

The methods developed by Dr. Angel's team can be used with a wide range of reprogramming factors and cell types, and the company is making chemically-defined, animal component-free versions of its products available for therapeutic applications. Dr. Angel's goal is to deploy the technology as widely as possible through a combination of products, services, and partnerships. "Factor Bioscience is a unique company, owned and operated entirely by scientists. The development of the first reliable RNA-reprogramming technology is the perfect example of what is possible in this environment."

About Factor Bioscience
Founded in 2011, Factor Bioscience develops nucleic-acid and cell-based research tools and therapeutics using its patented and patent-pending reprogramming and gene-editing technologies. For more information, visit www.factorbio.com, and follow us on Twitter at @factorbio.

The content of this press release is the sole responsibility of the authors and does not necessarily represent the official views of the USPTO.


'/>"/>
SOURCE Factor Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Announces 2012 Journal Impact Factor Highlights
2. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
3. Latest Cell Publication of OriGene and Peking University Collaborative Discovery of New iPSC Reprogramming Factors
4. New study identifies the role of a key growth factor in promoting formation of hair follicles and suggests a new therapeutic approach to treat baldness
5. Cell Culture Market (Media, Sera, Reagents, Serum-Free Media, Albumin, Growth Factors & Cytokines, Instruments, Bioreactors, Roller Bottle Equipment, T-Flasks And Cryostorage Equipment) - Global Industry Analysis, Size, Share, Growth, Trends And For
6. Researchers identify transcription factors that regulate retinal vascularization
7. ChemAxon Provides Chemistry Informatics Platform for the European Lead Factory
8. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
9. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
10. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
11. The X factor in liver metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia Inc. ... , a provider of whole slide imaging solutions, are hosting a pre-conference workshop ... entitled “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, ...
(Date:9/20/2017)... ... September 20, 2017 , ... Foresight Institute, a ... other transformative technologies, announced the winners for the 2017 Foresight Institute Feynman Prizes.These ... in nanotechnology/molecular manufacturing. , Established in 1993 and named in honor of pioneer ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... standard fume hood and a high-performance fume hood. Along with the advantages and ... applications for ductless vs. ducted hoods in the laboratory. , Attendees will learn ...
(Date:9/19/2017)... ... September 19, 2017 , ... The new and improved Oakton® pocket testers, from ... stand upright with a new cap design that is versatile, functional and leakproof. They ... need to test water quality. , The Oakton pocket testers have many user-friendly and ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):